The Microbiome Movement Drug Development Europe covers topics such as:
- Building a Leading Microbiome Company: How to put Your Foot Firmly in the European Market
- Developing Microbiome Based Therapeutics: Leveraging Technology and Product Innovation to Develop Characterization Plans
- How to Turn Outstanding Microbiome Science into an Effective & Efficient Product
- GxP Sequencing Services & The Future of Microbiome Analysis
- Overcoming Preclinical Challengesa
- Establishing The First WHO International Reference Reagents for Microbiome Analysis
- Engineered Enzymes Precisely Modifying Bile Acids, Treating Non Alcoholic Fatty Liver Disease (NAFLD) and Hyperlipidemia
- Evaluating a Next Generation LBP Therapy for Patients with Dravet and ALS
- Exploring the Latest Clinical Developments
- Developing Microbiome Ecosystem Therapies Aiming to Improve Outcomes for Patients with Liquid Tumours
- The benefits of the Capsugel® Enprotect® capsule for your Future Product Development
- MH002, a 6-strain Optimized Consortium in Clinical Development for Ulcerative Colitis & Pouchitis
- Microbiota in the ICU, Can We Anticipate New Targets?
- A High-Throughput Screening Approach to Study Effects of a Multi-Strain Product in the Colon Using Rapid Metabolic Fingerprintingt
- Rationally Designed LBPs- From Computational & Pre-clinical Data to Clinical Studies
- The Leading CDMO for Live Biotherapeutic Products, Biose Was Founded Over 70 Years Ago and Has Been Manufacturing Bacteria As a Drug Under GMP Conditions Since Then. Heres’ a Few FACTs:
- Potency, Dosing, Safety, Toxicology & More: Ensuring Your Preclinical Trial Will Reach Endpoints
- Working With Microbiome Investors
- Expanding our knowledge of Microbiome Derived Therapeutics
- Start-up Landscape: Ensuring the Population Stays High
- Getting Right Data That Allows for a Partnership for Biotech Companies
- Drinks Reception
- How Have Organisations Navigated Their Regulatory Path?
- The Power of PoC: Quick Insights Into the Unknown
- Exploring the EU Proposal for a New SoHO Regulation and the Impact on Microbiome-based Medicinal Product Development
- Benefits of Single-Use vs. Stainless Steel Fermentation Technologies
- Technology Challenges of Co-Cultivation
- CORAL® Platform as Engine for Design of Optimized Consortia Therapeutics – Therapeutic Program in Spondyloarthritis
- PharmaBiome NicheMap™: Deciphering the Interactions That Shape Microbiomes. Bringing
- Microbiome meets Spatial Transcriptomics
- The Microbiome Drug Development Searchlight Network is Challenging Traditional Thinking with how Drug Development is Done in the Microbiome Space
- Examining Development & Manufacturing Approaches: Implications on the Long-Term Impact
- The Potential of Using CRISPR Technology for Microbial Gene Therapy
- Reprogramming the Microbiome in Cancer Immunotherapy
- Microbiome Therapeutics: Key Challenges in Market Access
- The Microbiome and Antibiotic Resistance: Opportunities for the Microbiome Business Plan
- Landscape Review and Future Outlooks of Microbiome Therapeutics
The Microbiome Movement Drug Development Europe might be held in Jan 2025.
